Base editing finds a workaround for misfolded NPC1 protein
Therapeutic base editing has been limited by a blunt reality: many disease-causing missense variants cannot be cleanly repaired back to the wild-type sequence. This preprint tackles that problem from a different angle. Instead of trying to erase the original mutation, investigators searched for second-site changes inside NPC1 that could rescue folding, restore trafficking, and recover function in Niemann-Pick type C disease models.
The strategy matters because NPC1 sits at the center of lysosomal cholesterol transport. When the protein misfolds, it is trapped on the way to its normal cellular destination, cholesterol accumulates, and cells lose the ability to clear lipid cargo efficiently. A direct correction is ideal, but when the disease allele is inaccessible to standard editing, a compensatory mutation can shift the protein back into a functional state.
Tiled mutagenesis exposes rare suppressors across the endogenous locus
Investigators used tiled adenine and cytosine base editing screens across the endogenous NPC1 locus in haploid human cells carrying the common NPC1I1061T disease allele. That design let them interrogate a wide swath of the protein sequence in its native genomic setting rather than relying on overexpression systems that can distort folding behavior. Two phenotypic readouts anchored the screen: cholesterol transport and protein abundance.
The result was a map of intragenic suppressor mutations spread across multiple domains of the protein. These were not limited to a single obvious structural patch. Instead, the screen uncovered rare second-site variants that improved the behavior of the mutant protein through several mechanisms that appear tightly linked: greater stability, more efficient endoplasmic reticulum exit, and better lysosomal trafficking.
One finding stood out sharply.
A promiscuous second-site variant was able to correct multiple different pathogenic NPC1 mutations, not just the starting allele used in the screen.
Protein stability and trafficking moved in the same direction
The biology here is coherent. Misfolded membrane proteins are often destroyed before they reach their site of action, so a mutation that stabilizes the fold can have downstream effects on abundance, maturation, and intracellular routing. In this case, the corrector mutations improved protein stability and promoted movement out of the endoplasmic reticulum, where quality-control machinery would otherwise retain a defective species. Once trafficking improved, lysosomal delivery followed, which is exactly where NPC1 must operate to clear cholesterol.
That chain of events explains why the screen used both abundance and transport as phenotypic reporters. A corrector that merely raises protein levels without restoring the proper conformation would be biologically hollow. Here, the variants appeared to act on the underlying folding defect rather than offering a superficial signal.
Rescue extended into patient-derived cells and induced neurons
The work did not stop at engineered screening cells. The identified corrector mutations restored cholesterol clearance in patient-derived fibroblasts and in induced neurons. Those systems matter because they bring the findings closer to the tissues and cell types affected in human disease. Fibroblasts provide a disease-relevant readout of lipid handling, while neurons are particularly important for Niemann-Pick type C, where neurodegeneration is a major clinical burden.
This is where the translational logic becomes strongest. If a second-site edit can salvage a misfolded protein in patient-derived cells, it creates a route for therapy even when the original pathogenic base cannot be reversed directly. For alleles that are structurally difficult, nucleotide conversion may be less useful than an engineered detour that restores enough conformational stability for the protein to function.
A new use for base editing screens in protein rescue
The study reframes base editing as more than a correction tool. It becomes a discovery platform for repair-by-compensation. By tiling the endogenous gene and watching for functional rescue, investigators can identify suppressor mutations that are invisible to standard variant-to-wild-type thinking. In a protein like NPC1, where pathogenicity often stems from misfolding and defective trafficking, that approach is especially well suited.
The broader implication is clear for inherited diseases driven by structurally fragile proteins. Some disease alleles may remain out of reach for exact correction, but the protein itself can still be manipulated into a usable state if the right second-site change is found. This is a more flexible therapeutic logic, and it fits diseases in which residual function is enough to change the cell’s behavior.
Why the screen design matters for future therapy
A native-locus screen preserves the chromatin context, the endogenous expression level, and the protein’s normal cellular environment. Those features are not cosmetic. Folding defects, trafficking checkpoints, and degradation pathways all operate differently when a protein is produced at physiological levels inside its proper genomic setting. Tiled base editing also makes it possible to search systematically rather than guessing where a suppressor might lie.
The approach could be extended to other misfolded disease proteins, especially when the pathogenic mechanism involves protein stability, ER quality control, or defective organelle delivery. It may also help separate mutations that destroy catalytic function from mutations that mainly destabilize the fold, since the rescue logic depends on preserving enough structural integrity for the protein to reach its destination.
For now, this remains a preprint and has not undergone peer review. Even so, the experimental path is unusually direct: search the endogenous gene, identify suppressors, test them in disease-relevant cells, and ask whether function returns. The remaining questions are practical ones about generalizability, delivery, and whether second-site editing can be translated into a safe clinical strategy for a lysosomal disorder with complex tissue involvement.